Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives $16.00 Average PT from Analysts

Tenax Therapeutics, Inc. (NASDAQ:TENX) has received an average rating of “Buy” from the five ratings firms that are covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $16.00.

Several analysts have commented on the company. William Blair initiated coverage on Tenax Therapeutics in a report on Monday, September 30th. They issued an “outperform” rating for the company. StockNews.com assumed coverage on shares of Tenax Therapeutics in a report on Thursday, September 26th. They issued a “sell” rating for the company. Guggenheim began coverage on shares of Tenax Therapeutics in a research note on Monday, October 14th. They set a “buy” rating and a $16.00 price target on the stock. Leerink Partnrs upgraded shares of Tenax Therapeutics to a “strong-buy” rating in a report on Thursday, October 24th. Finally, Leerink Partners began coverage on Tenax Therapeutics in a report on Thursday, October 24th. They set an “outperform” rating and a $16.00 price objective for the company.

Institutional Trading of Tenax Therapeutics

Hedge funds have recently made changes to their positions in the company. Sphera Funds Management LTD. purchased a new position in shares of Tenax Therapeutics during the 3rd quarter valued at approximately $101,000. Stonepine Capital Management LLC bought a new position in shares of Tenax Therapeutics during the third quarter valued at approximately $173,000. Finally, Vestal Point Capital LP bought a new position in Tenax Therapeutics during the 3rd quarter worth $288,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Stock Down 5.0 %

Shares of NASDAQ:TENX opened at $5.52 on Friday. The business has a fifty day simple moving average of $4.91 and a 200-day simple moving average of $4.00. Tenax Therapeutics has a 52 week low of $2.77 and a 52 week high of $27.33.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.